{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:09:05Z","timestamp":1779246545147,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.biopha.2026.119242","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T13:48:10Z","timestamp":1774100890000},"page":"119242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Analysis of the relationship between body composition and the pharmacokinetics of panitumumab in the treatment of localized squamous cell carcinoma of the anus \u2013 An ancillary study of the FFCD0904 phase I and II trial"],"prefix":"10.1016","volume":"198","author":[{"given":"Sarah","family":"Lobet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ternant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Come","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3226-8525","authenticated-orcid":false,"given":"Karine","family":"Le Malicot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Azzopardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6878-0168","authenticated-orcid":false,"given":"Adeline","family":"Dolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Lagogu\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Bazire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Lemanski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Martin-Babau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Li\u00e8vre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"De la Fouchardi\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meher","family":"Ben Abdelghani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Paintaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Vendrely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5093-0212","authenticated-orcid":false,"given":"Thierry","family":"Lecomte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119242_bib1","first-page":"942","article-title":"Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification","volume":"19","author":"Alvarez","year":"2006","journal-title":"Mod. Pathol. J. U S Can. Acad. Pathol. Inc."},{"key":"10.1016\/j.biopha.2026.119242_bib2","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/annonc\/mdt368","article-title":"Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial","volume":"24","author":"Deutsch","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2026.119242_bib3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.radonc.2015.02.008","article-title":"Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Longterm results of the UNICANCER ACCORD 16 phase II trial","volume":"114","author":"Levy","year":"2015","journal-title":"Radio. Oncol."},{"key":"10.1016\/j.biopha.2026.119242_bib4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2016.69.1642","article-title":"Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial","volume":"35","author":"Sparano","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119242_bib5","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1200\/JCO.2016.69.1667","article-title":"Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205)","volume":"35","author":"Garg","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119242_bib6","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1200\/JCO.2016.69.1667","article-title":"Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205)","volume":"35","author":"Garg","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119242_bib7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.critrevonc.2018.01.007","article-title":"Treatment of squamous cell carcinoma of the anal canal: a new strategies with anti-EGFR therapy and immunotherapy","volume":"123","author":"Casadei Gardini","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.biopha.2026.119242_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109742","article-title":"Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial","volume":"186","author":"Vendrely","year":"2023","journal-title":"Radio. Oncol."},{"key":"10.1016\/j.biopha.2026.119242_bib9","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1158\/1078-0432.CCR-18-0415","article-title":"Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance","volume":"24","author":"Turner","year":"2018","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2026.119242_bib10","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/cpt.1953","article-title":"Characterizing exposureresponse relationship for therapeutic monoclonal antibodies in immuno-oncology and beyond: challenges, perspectives, and prospects","volume":"108","author":"Dai","year":"2020","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2026.119242_bib11","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1111\/bcp.14662","article-title":"Confounding factors in exposure\u2013response analyses and mitigation strategies for monoclonal antibodies in oncology","volume":"87","author":"Kawakatsu","year":"2021","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2026.119242_bib12","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1139\/H08-075","article-title":"A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care","volume":"33","author":"Mourtzakis","year":"2008","journal-title":"Appl. Physiol. Nutr. Metab."},{"key":"10.1016\/j.biopha.2026.119242_bib13","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3390\/nu14071526","article-title":"What Is a 2021 Reference Body?","volume":"14","author":"M\u00fcller","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2026.119242_bib14","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/17512433.2017.1347503","article-title":"A review of body composition and pharmacokinetics in oncology","volume":"10","author":"Hopkins","year":"2017","journal-title":"Expert Rev. Clin. Pharm."},{"key":"10.1016\/j.biopha.2026.119242_bib15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13014-021-01876-5","article-title":"Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer","volume":"16","author":"Nilsson","year":"2021","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.biopha.2026.119242_bib16","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.3390\/cancers14184521","article-title":"Body Composition as a Predictor of the Survival in Anal Cancer","volume":"14","author":"Mohamed","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119242_bib17","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/jso.25887","article-title":"Sarcopenia is associated with worse overall survival in patients with anal squamous cell cancer","volume":"121","author":"Bingmer","year":"2020","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.biopha.2026.119242_bib18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.radonc.2019.05.018","article-title":"Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904)","volume":"140","author":"Vendrely","year":"2019","journal-title":"Radio. Oncol."},{"key":"10.1016\/j.biopha.2026.119242_bib19","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1152\/japplphysiol.00744.2004","article-title":"Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image","volume":"97","author":"Shen","year":"2004","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.biopha.2026.119242_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4155\/bio-2016-0292","article-title":"Development and validation of an ELISA to study panitumumab pharmacokinetics","volume":"10","author":"Desvignes","year":"2018","journal-title":"Bioanalysis"},{"key":"10.1016\/j.biopha.2026.119242_bib21","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1177\/0091270009344989","article-title":"Population Pharmacokinetic Analysis of Panitumumab in Patients With Advanced Solid Tumors","volume":"49","author":"Ma","year":"2009","journal-title":"J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119242_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2026.119242_bib23","article-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2021","journal-title":"R. Found. Stat. Comput."},{"key":"10.1016\/j.biopha.2026.119242_bib24","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1158\/1078-0432.CCR-18-0415","article-title":"Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance","volume":"24","author":"Turner","year":"2018","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2026.119242_bib25","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/cpt.1953","article-title":"Characterizing Exposure-Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects","volume":"108","author":"Dai","year":"2020","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2026.119242_bib26","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1111\/bcp.14662","article-title":"Confounding factors in exposure-response analyses and mitigation strategies for monoclonal antibodies in oncology","volume":"87","author":"Kawakatsu","year":"2021","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2026.119242_bib27","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1016\/j.clnu.2020.02.017","article-title":"Concurrent losses of skeletal muscle mass, adipose tissue and bone mineral density during bevacizumab \/ cytotoxic chemotherapy treatment for metastatic colorectal cancer","volume":"39","author":"Dolly","year":"2020","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.biopha.2026.119242_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2019.06.020","article-title":"Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival","volume":"67-68","author":"Ryan","year":"2019","journal-title":"Nutrition"},{"key":"10.1016\/j.biopha.2026.119242_bib29","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1158\/1078-0432.CCR-06-3067","article-title":"Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity","volume":"13","author":"Prado","year":"2007","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2026.119242_bib30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/cam4.621","article-title":"Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens","volume":"5","author":"Ali","year":"2016","journal-title":"Cancer Med"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226002751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226002751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:50:58Z","timestamp":1779245458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226002751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":30,"alternative-id":["S0753332226002751"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119242","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of the relationship between body composition and the pharmacokinetics of panitumumab in the treatment of localized squamous cell carcinoma of the anus \u2013 An ancillary study of the FFCD0904 phase I and II trial","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119242"}}